The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The SOCS Box of SOCS-1 Accelerates Ubiquitin-dependent Proteolysis of TEL-JAK2
Open accessAbstract
Fusion of the TEL gene on 12p13 to the JAK2 tyrosine kinase gene on 9p24 has been found in human leukemia. TEL-mediated oligomerization of JAK2 results in constitutive activation of the tyrosine kinase (JH1) domain and confers cytokine-independent proliferation on interleukin-3-dependent Ba/F3 cells. Forced expression of the JAK inhibitor gene SOCS1/JAB/SSI-1 induced apoptosis of TEL-JAK2-transformed Ba/F3 cells. This suppression of TEL-JAK2 activity was dependent on SOCS box-mediated proteasomal degradation of TEL-JAK2 rather than on kinase inhibition. Degradation of JAK2 depended on its phosphorylation and its high affinity binding with SOCS1 through the kinase inhibitory region and the SH2 domain. It has been demonstrated that von Hippel-Lindau disease (VHL) tumor-suppressor gene product possesses the SOCS box that forms a complex with Elongin B and C and Cullin-2, and it functions as a ubiquitin ligase. The SOCS box of SOCS1/JAB has also been shown to interact with Elongins; however, ubiquitin ligase activity has not been demonstrated. We found that the SOCS box interacted with Cullin-2 and promoted ubiquitination of TEL-JAK2. Furthermore, overexpression of dominant negative Cullin-2 suppressed SOCS1-dependent TEL-JAK2 degradation. Our study demonstrates the substrate-specific E3 ubiquitin-ligase-like activity of SOCS1 for activated JAK2 and may provide a novel strategy for the suppression of oncogenic tyrosine kinases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ablation of TCEB2, a binding partner of SOCS1, also improved tumor clearance, suggesting that the SOCS1/TCEB2 complex restrains T cell responses and is a potential target for immunotherapy (Ilangumaran et al., 2017; Kamizono et al., 2001; Liau et al., 2018).”
From Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function (2018) · cites this paper as Kamizono et al., 2001
Citations
Cites
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
A family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
A new protein containing an SH2 domain that inhibits JAK kinases
Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., et al. (1997) · Nature · doi:10.1038/43213 · Cited by 1,408
Self-citationStructure and function of a new STAT-induced STAT inhibitor
Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. (1997) · Nature · doi:10.1038/43219 · Cited by 1,040
The Tyrosine Kinase Negative Regulator c-Cbl as a RING-Type, E2-Dependent Ubiquitin-Protein Ligase
Joazeiro, C. A. P., Wing, S. S., Huang, H.-K., Leverson, J. D., Hunter, T., & Liu, Y.-C. (1999) · Science · doi:10.1126/science.286.5438.309 · Cited by 1,034
Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80231-2 · Cited by 1,001
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80047-1 · Cited by 762
Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Hara, T., & Miyajima, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07281.x · Cited by 753
Self-citationTwenty proteins containing a C-terminal SOCS box form five structural classes
Hilton, D. J., Richardson, R. T., Alexander, W. S., Viney, E. M., Willson, T. A., Sprigg, N. S., Starr, R., Nicholson, S. E., Metcalf, D., & Nicola, N. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.114 · Cited by 733
Research works printed but not linked: 1
- Shuai, 1996, Oncogene, 13, 247
Cited by
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
“Furthermore, SOCS promote interactions that lead to ubiquitination and proteasome degradation of components of the JAK/STAT signaling (104, 105).”
BackgroundJanus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
“Importantly, the mutation-based constitutive activation of Jak can still be controlled by induced expression of specific Jak phosphatases, SOCS proteins or by kinase inhibitors that are currently used in clinical trials (116, 117) (Fig.”
BackgroundO'Shea, J. J., Gadina, M., & Schreiber, R. D. (2002) · Cell · doi:10.1016/s0092-8674(02)00701-8 · Cited by 1,119
SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2
Rui, L., Yuan, M., Frantz, D., Shoelson, S., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200444200 · Cited by 904
Cytokine Signaling Modules in Inflammatory Responses
O'Shea, J. J., & Murray, P. J. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.002 · Cited by 818
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 768
“unique motif which is not only found in this family, but also can be explored in other miscellaneous proteins [55].”
BackgroundAlexander, W. S., & Hilton, D. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.091003.090312 · Cited by 701
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004) · Leukemia · doi:10.1038/sj.leu.2403241 · Cited by 684
Transcriptional Mechanisms Underlying Lymphocyte Tolerance
Macián, F., Garcı́a-Cózar, F., Im, S.-H., Horton, H. F., Byrne, M. C., & Rao, A. (2002) · Cell · doi:10.1016/s0092-8674(02)00767-5 · Cited by 687
Ueki, K., Kondo, T., & Kahn, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5434-5446.2004 · Cited by 686
“SOCS-1, but not SOCS-3, has been reported to interact with and promote ubiquitin-mediated degradation of some proteins through its carboxyl-terminal region (SOCS-box) as part of a ubiquitin-ligase complex (8, 22, 23).”
BackgroundSuppressors of cytokine signalling (SOCS) in the immune system
Alexander, W. S. (2002) · Nature Reviews Immunology · doi:10.1038/nri818 · Cited by 645
“Although, as expected, SOCS1 inhibited the catalytic activity of the fusion protein, full suppression relied on the SOCS-box-dependent ubiquitination of TEL–JAK2 and was not achieved in the presence of proteasome inhibitor”
SOCS regulation of the JAK/STAT signalling pathway
Croker, B. A., Kiu, H., & Nicholson, S. E. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.010 · Cited by 611
Ryo, A., Suizu, F., Yoshida, Y., Perrem, K., Liou, Y.-C., Wulf, G., Rottapel, R., Yamaoka, S., & Lu, K. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00490-8 · Cited by 637
SOCS1/JAB Is a Negative Regulator of LPS-Induced Macrophage Activation
Kinjyo, I., Hanada, T., Inagaki-Ohara, K., Mori, H., Aki, D., Ohishi, M., Yoshida, H., Kubo, M., & Yoshimura, A. (2002) · Immunity · doi:10.1016/s1074-7613(02)00446-6 · Cited by 630
Self-citationSuppressors of cytokine signaling and immunity
Kubo, M., Hanada, T., & Yoshimura, A. (2003) · Nature Immunology · doi:10.1038/ni1012 · Cited by 618
“The fact that SOCS1-mediated suppression of TEL-JAK2 oncogenic activit”
BackgroundSelf-citationGenome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell · doi:10.1016/j.cell.2018.10.024 · Cited by 573
Mansell, A., Smith, R., Doyle, S. L., Gray, P., Fenner, J. E., Crack, P. J., Nicholson, S. E., Hilton, D. J., O'Neill, L. A. J., & Hertzog, P. J. (2006) · Nature Immunology · doi:10.1038/ni1299 · Cited by 514
“We found that Mal associates with SOCS-1, which acts as an E3 ligas”
BackgroundKamura, T., Maenaka, K., Kotoshiba, S., Matsumoto, M., Kohda, D., Conaway, R. C., Conaway, J. W., & Nakayama, K. I. (2004) · Genes & Development · doi:10.1101/gad.1252404 · Cited by 477
“…respectively We previously showed that VHL interacts specifically with the Cul2–Rbx1 module under physiological conditions (Kamura et al. 1999), but that it also associates with Cul5–Rbx1 when VHL, Elongin B, Elongin C, Cul5, and Rbx1 are overexpressed in Sf21 insect cells (Kamura et al. 2001).”
BackgroundSelf-citationA hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin
Willems, A. R., Schwab, M., & Tyers, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.027 · Cited by 464
Tebbutt, N. C., Giraud, A. S., Inglese, M., Jenkins, B., Waring, P., Clay, F. J., Malki, S., Alderman, B. M., Grail, D., Hollande, F., et al. (2002) · Nature Medicine · doi:10.1038/nm763 · Cited by 474
“, which reduces kinase-dependent receptor Y-phosphorylation and mediates ubiquitination of receptor associated Jak kinase”
BackgroundThe molecular basis of JAK/STAT inhibition by SOCS1
Liau, N. P. D., Laktyushin, A., Lucet, I. S., Murphy, J. M., Yao, S., Whitlock, E., Callaghan, K., Nicola, N. A., Kershaw, N. J., & Babon, J. J. (2018) · Nature Communications · doi:10.1038/s41467-018-04013-1 · Cited by 456
Inhibitors of Cytokine Signal Transduction
Wormald, S., & Hilton, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r300030200 · Cited by 440
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer
He, B., You, L., Uematsu, K., Zang, K., Xu, Z., Lee, A. Y., Costello, J. F., McCormick, F., & Jablons, D. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232790100 · Cited by 380
Niwa, Y., Kanda, H., Shikauchi, Y., Saiura, A., Matsubara, K., Kitagawa, T., Yamamoto, J., Kubo, T., & Yoshikawa, H. (2005) · Oncogene · doi:10.1038/sj.onc.1208788 · Cited by 339
“…interacts with phosphorylated tyrosine in other molecules, the SOCS box, another domain in SOCS proteins, is able to interact with Elongins B and C, and couples the SH2 domain-binding proteins to the ubiquitin-proteasome pathway (Zhang et al., 1999; Kamizono et al., 2001; Sasaki et al., 2003).”
BackgroundTamiya, T., Kashiwagi, I., Takahashi, R., Yasukawa, H., & Yoshimura, A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207464 · Cited by 322
Self-citationKershaw, N. J., Murphy, J. M., Liau, N. P. D., Varghese, L. N., Laktyushin, A., Whitlock, E. L., Lucet, I. S., Nicola, N. A., & Babon, J. J. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2519 · Cited by 301
“Mouse JAK2 JH1 domain (residues 836–1132) was coexpressed with the phosphatase PTP1B (residues 2–321) in Sf21 insect cells to obtain activation loop–dephosphorylated JAK2 JH1.”
MethodInfluentialSubramaniam, A., Shanmugam, M. K., Perumal, E., Li, F., Nachiyappan, A., Dai, X., Swamy, S. N., Ahn, K. S., Kumar, A. P., Tan, B. K. H., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.002 · Cited by 278
“SOCS1 inhibits JAK activation through its N-terminal kinase inhibitory region (KIR) by direct binding to the activation loop of JAKs, while SOCS3 inhibits JAK kinase by binding to the cytokine receptor through its SH2 domain [174,176].”
BackgroundBabon, J. J., Kershaw, N. J., Murphy, J. M., Varghese, L. N., Laktyushin, A., Young, S. N., Lucet, I. S., Norton, R. S., & Nicola, N. A. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.015 · Cited by 279
“, 1998), which interacts with elongins B and C and Cullin5 to catalyze the ubiquitination of bound signaling proteins (Babon et al., 2009; Kamizono et al., 2001; Zhang et al., 1999).”
Baetz, A., Frey, M., Heeg, K., & Dalpke, A. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410992200 · Cited by 270
SOCS, Inflammation, and Autoimmunity
Yoshimura, A., Suzuki, M., Sakaguchi, R., Hanada, T., & Yasukawa, H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00020 · Cited by 254
“The SOCS box interacts with elongin B and elongin C, Cullins, and the RING-finger-domain-only protein RBX2 (which recruits E2 ubiquitin-transferase; Kamizono et al., 2001; Kamura et al., 2004).”
BackgroundSelf-citationUngureanu, D., Saharinen, P., Junttila, I., Hilton, D. J., & Silvennoinen, O. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3316-3326.2002 · Cited by 260
“Recently SOCS-1 was shown to mediate the growth inhibition of TEL-Jak2-transformed cells and to accelerate the proteasomal degradation of the oncogenic, hyperactive TEL-Jak2 and gyrase B-Jak2 chimeras, neither of which is activated in response to cytokines (13, 20).”
BackgroundImmunity by ubiquitylation: a reversible process of modification
Liu, Y.-C., Penninger, J., & Karin, M. (2005) · Nature Reviews Immunology · doi:10.1038/nri1731 · Cited by 257
“Consistent with predictions from its structure, SOCS1 has been shown to promote the conjugation of ubiquitin to JAK2, VAV1 and the p65 subunit of NF-κB (also known as REL-A) [96] [97] [98] .”
JAK/STAT signal transduction: Regulators and implication in hematological malignancies
Valentino, L., & Pierre, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.017 · Cited by 251
Regulation of apoptosis: the ubiquitous way
Yang, Y., & Xiaodan, Y. (2003) · The FASEB Journal · doi:10.1096/fj.02-0654rev · Cited by 251
“It has been shown that SOCS1 can act as an adaptor to facilitate ubiquitination and degradation of proteins bound to its SH2 domain, such as oncogenic fusion protein Tel-JAK2 (66, 67) and guanine nucleotide exchange factor Vav (68).”
BackgroundLoss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production
Ogata, H., Chinen, T., Yoshida, T., Kinjyo, I., Takaesu, G., Shiraishi, H., Iida, M., Kobayashi, T., & Yoshimura, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209281 · Cited by 246
“Oncogene (2006) 25, 2520–2530 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc domain-binding proteins to the ubiquitin–proteasome pathway (Kamura et al., 1998; Kamizono et al., 2001).”
BackgroundInfluentialSelf-citationTherapeutic targeting of Janus kinases
Pesu, M., Laurence, A., Kishore, N., Zwillich, S. H., Chan, G., & O'Shea, J. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00644.x · Cited by 231
“In addition, SOCS1 forms an E3 ubiquitin ligase complex with elongins B and C, Cullin-5 (Cul-5), and Rbx1 to mediate the ubiquitination of JAKs, which may promote proteasomedependent degradation (23, 24).”
BackgroundSuppressor of Cytokine Signaling 3 Is a Physiological Regulator of Adipocyte Insulin Signaling
Shi, H., Tzameli, I., Bjørbæk, C., & Flier, J. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403886200 · Cited by 222
Differential hypermethylation of SOCS genes in ovarian and breast carcinomas
Sutherland, K. D., Lindeman, G. J., Choong, D. Y. H., Wittlin, S., Brentzell, L., Phillips, W., Campbell, I. G., & Visvader, J. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207787 · Cited by 217
“These proteins also target the signaling proteins to which they bind for ubiquitination and proteasomal degradation, thereby contributing to the tight regulation of cytokine signaling (Ram and Waxman, 2000; Kamizono et al., 2001).”
BackgroundE3 ubiquitin ligases as regulators of membrane protein trafficking and degradation
d'Azzo, A., Bongiovanni, A., & Nastasi, T. (2005) · Traffic · doi:10.1111/j.1600-0854.2005.00294.x · Cited by 206
Negative Regulation of Cytokine Signaling in Immunity
Yoshimura, A., Ito, M., Chikuma, S., Akanuma, T., & Nakatsukasa, H. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028571 · Cited by 196
“2) (Hilton et al. 1998; Kamizono et al. 2001; Kamura et al. 2004).”
Self-citationCish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance
Palmer, D. C., Guittard, G. C., Franco, Z., Crompton, J. G., Eil, R. L., Patel, S. J., Ji, Y., Van Panhuys, N., Klebanoff, C. A., Sukumar, M., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150304 · Cited by 200
SOCS proteins in development and disease.
Trengove, M. C., & Ward, A. C. (2013) · Europe PMC (PubMed Central) · Cited by 235
NEDD8 Pathways in Cancer, Sine Quibus Non
Watson, I. R., Irwin, M. S., & Ohh, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.002 · Cited by 181
Negative Regulation of Growth Hormone Receptor Signaling
Flores-Morales, A., Greenhalgh, C. J., Norstedt, G., & Rico-Bautista, E. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0170 · Cited by 183
“In line with its proposed role as ubiquitin ligase, SOCS1 induces the proteasomal degradation of guanine nucleotide exchange factor Vav (79), oncogene Tel-JAK2 (80, 81), JAK2 (Fig.”
BackgroundThe many faces of the SOCS box
Piessevaux, J., Lavens, D., Peelman, F., & Tavernier, J. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.08.006 · Cited by 176
“SOCS1 promotes the ubiquitination and turnover of JAK2 and the TEL-JAK2 oncogene in a SOCS box-dependent fashion [33–35].”
BackgroundControl mechanism of JAK/STAT signal transduction pathway
Yamada, S., Shiono, S., Joo, A., & Yoshimura, A. (2003) · FEBS Letters · doi:10.1016/s0014-5793(02)03842-5 · Cited by 184
Self-citationThe suppressors of cytokine signalling (SOCS)
Kile, B. T., & Alexander, W. S. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000801 · Cited by 175
An intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells
Ohh, M., Kim, W. Y., Moslehi, J. J., Chen, Y., Chau, V., Read, M. A., & Kaelin, W. G. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf028 · Cited by 177
“Replacement of pVHL with SOCS1, which contains a region that is similar to the pVHL α domain, generates an E3 ligase implicated in the ubiquitylation of VAV and TEL-JAK2 (De Sepulveda et al., 2000; Frantsve et al., 2001; Kamizono et al., 2001).”
BackgroundSignal transducer and activator of transcription (STAT) signalling and T‐cell lymphomas
Mitchell, T. J., & John, S. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02091.x · Cited by 163
Negative regulation of cytokine signaling and immune responses by SOCS proteins.
Yoshimura, A., Nishinakamura, H., Matsumura, Y., & Hanada, T. (2005) · Arthritis Research · doi:10.1186/ar1741 · Cited by 182
Self-citationSands, W. A., Woolson, H. D., Milne, G. R., Rutherford, C. L., & Palmer, T. M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00207-06 · Cited by 157
“In addition, the C-terminal “SOCS box” domain can target SH2 domain-bound partners for proteasomal degradation by directing interaction with an elongin B/C-Cul5-Rbx1 complex to form an E3 ubiquitin ligase (23, 38).”
BackgroundZhang, J.-G., Metcalf, D., Rakar, S., Asimakis, M., Greenhalgh, C., Willson, T., Starr, R., Nicholson, S., Carter, W., Alexander, W., et al. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.231486498 · Cited by 189
Kamura, T., Burian, D., Yan, Q., Schmidt, S. L., Lane, W. A. S., Querido, E., Branton, P., Shilatifard, A., Conaway, R., & Conaway, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103093200 · Cited by 183
Krebs, D. L., Uren, R. T., Metcalf, D., Rakar, S., Zhang, J., Starr, R., Souza, D. P. D., Hanzinikolas, K., Eyles, J. L., Connolly, L., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4567-4578.2002 · Cited by 163
“In addition, the ubiquitination and degradation of Tel-Jak2 occur in a SOCS box-dependent manner (11, 16).”
BackgroundSuppressors of Cytokine Signaling 4 and 5 Regulate Epidermal Growth Factor Receptor Signaling
Kario, E., Marmor, M. D., Adamsky, K., Citri, A., Amit, I., Amariglio, N., Rechavi, G., & Yarden, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408575200 · Cited by 151
SOCS2 Can Enhance Interleukin-2 (IL-2) and IL-3 Signaling by Accelerating SOCS3 Degradation
Tannahill, G., Elliott, J., Barry, A., Hibbert, L., Cacalano, N., & Johnston, J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.20.9115-9126.2005 · Cited by 158
“blast transform leukemia-JAK2 fusion protein) (9, 23).”
Cullin 5 regulates Dab1 protein levels and neuron positioning during cortical development
Feng, L., Allen, N. S., Simo, S., & Cooper, J. A. (2007) · Genes & Development · doi:10.1101/gad.1604207 · Cited by 148
“Kamizono et al. (2001) found that overexpression of a mutant Cul2 inhibits SOCS1-stimulated degradation of a tyrosine-phosphorylated substrate.”
BackgroundMultiple degradation pathways regulate versatile CIP/KIP CDK inhibitors
Starostina, N. G., & Kipreos, E. T. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.004 · Cited by 147
SCF E3 Ubiquitin Ligases as Anticancer Targets
Jia, L., & Sun, Y. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519734 · Cited by 147
Babon, J., Sabo, J. K., Zhang, J.-G., Nicola, N., & Norton, R. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.024 · Cited by 155
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
Pesu, M., Candotti, F., Husa, M., Hofmann, S. R., Notarangelo, L. D., & O’Shea, J. J. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00220.x · Cited by 134
“Because the kinase domain–pseudokinase architecture is a unique feature of the Jaks, there is little additional information that offers insights into how this regulation occurs.”
BackgroundInfluentialIvo, P. T. (2006) · Frontiers in bioscience · doi:10.2741/2103 · Cited by 138
“This may contribute to ubiquitination and subsequent proteasomal degradation of signaling molecules (142-145).”
BackgroundEmerging roles for the IL-6 family of cytokines in pancreatic cancer
van Duijneveldt, G., Griffin, M. D. W., & Putoczki, T. L. (2020) · Clinical Science · doi:10.1042/cs20191211 · Cited by 137
The tumor suppressor activity of SOCS-1
Rottapel, R. K., Ilangumaran, S., Neale, C., Rose, J. L., Ho, J., Nguyen, M. H.-H., Barber, D. L., Dubreuil, P. C., & Sepulveda, P. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205537 · Cited by 139
“Three recent reports describe the promotion of TEL-JAK2 ubiquitination and degradation by SOCS-1 (Frantsve et al., 2001; Kamizono et al., 2001; Monni et al., 2001).”
BackgroundRegulation of the immune system by SOCS family adaptor proteins
Ilangumaran, S., Ramanathan, S., & Rottapel, R. K. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2004.08.015 · Cited by 145
Xia, L., Wang, L., Chung, A. S., Ivanov, S., Ling, M. Y., Dragoi, A. M., Platt, A., Gilmer, T., Fu, X.-Y., & Chin, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202823200 · Cited by 137
Gamma interferon: a central mediator in atherosclerosis
León, M. L. A., & Zuckerman, S. H. (2005) · Inflammation Research · doi:10.1007/s00011-005-1377-2 · Cited by 133
“SOCS-1 binds to and inhibits Jak2 kinase activity [58] and might also serve to target Jak2 for proteasomal degradation [59, 60].”
BackgroundSengupta, D., Koblansky, A. A., Gaines, J. M., Brown, T., West, A. P., Zhang, D., Nishikawa, T., Park, S., Roop, R. M., & Ghosh, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902008 · Cited by 124
“However, unlike SOCS-1, which is an E3 ubiquitin ligase (50, 51), TcpB has no obvious similarity to known ubiquitin ligases.”
BackgroundThe SOCS box—Adapting proteins for ubiquitination and proteasomal degradation
Linossi, E. M., & Nicholson, S. E. (2012) · IUBMB Life · doi:10.1002/iub.1011 · Cited by 122
Shi, H., Cave, B. J., Inouye, K., Bjørbæk, C., & Flier, J. S. (2006) · Diabetes · doi:10.2337/diabetes.55.03.06.db05-0841 · Cited by 130
“SOCS proteins in turn suppress cytokine signaling by directly inhibiting tyrosine-phosphorylated JAK or activated cytokine receptors (4) and/or by targeting signaling proteins for proteasomal degradation (5,6).”
Tyrosine Phosphorylation Disrupts Elongin Interaction and Accelerates SOCS3 Degradation*
Haan, S., Ferguson, P. R., Sommer, U., Hiremath, M. M., McVicar, D., Heinrich, P., Johnston, J., & Cacalano, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303170200 · Cited by 148
Functional Cross-modulation between SOCS Proteins Can Stimulate Cytokine Signaling*
Piessevaux, J., Lavens, D., Montoye, T., Wauman, J., Catteeuw, D., Vandekerckhove, J., Belsham, D., Peelman, F., & Tavernier, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600776200 · Cited by 121
SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation.
Davey, G. M., Heath, W., & Starr, R. (2006) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00532.x · Cited by 120
Signal transducer and activator of transcription 5A/B in prostate and breast cancers
Tan, S., & Nevalainen, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0013 · Cited by 128
“The SOCS proteins also appear to target signal transducers for proteasomal destruction (Zhang et al. 1999, Kamizono et al. 2001, Ungureanu et al. 2002).”
BackgroundTRIM8/GERP RING Finger Protein Interacts with SOCS-1
Toniato, E., Chen, X. P., Losman, J. A., Flati, V., Donahue, L., & Rothman, P. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205900200 · Cited by 123
Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy
Chikuma, S., Kanamori, M., Mise‐Omata, S., & Yoshimura, A. (2017) · Cancer Science · doi:10.1111/cas.13194 · Cited by 112
Self-citationQasimi, P., Ming‐Lum, A., Ghanipour, A., Ong, C. J., Cox, M., Ihle, J. N., Cacalano, N. A., Yoshimura, A., & Mui, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508608200 · Cited by 122
Self-citationSasi, W., Jiang, W. G., Sharma, A. K., & Mokbel, K. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-178 · Cited by 114
“CIS) are also involved in a fourth inhibitory mechanism which is their ability to accelerate proteasome-mediated destruction of the activated cytokine-receptor complex [19,20].”
BackgroundNegative regulation of FAK signaling by SOCS proteins
Liu, E., Côté, J., & Vuori, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg503 · Cited by 107
The SOCS Box Domain of SOCS3: Structure and Interaction with the ElonginBC-Cullin5 Ubiquitin Ligase
Babon, J. J., Sabo, J. K., Soetopo, A., Yao, S., Bailey, M. F., Zhang, J., Nicola, N. A., & Norton, R. S. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.06.038 · Cited by 113
Targeting STAT3 signaling in kidney disease
Pace, J. A., Paladugu, P., Das, B. C., He, C., & Mallipattu, S. K. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00034.2019 · Cited by 110
“AG490 is a JAK2 inhibitor that was discovered for its ability to block proliferation in a human B-precursor leukemic cell line (56).”
BackgroundInfluentialSignalling by the βc family of cytokines
Hercus, T. R., Dhagat, U., Kan, W. L., Broughton, S. E., Nero, T. L., Perugini, M., Sandow, J. J., D’Andrea, R. J., Ekert, P. G., Hughes, T. P., et al. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.03.002 · Cited by 113
“proteins which target JAK2 for ubiquitination and proteasomal degradation [156,157].”
BackgroundSOCS Proteins as Regulators of Inflammatory Responses Induced by Bacterial Infections: A Review
Duncan, S. A., Baganizi, D. R., Sahu, R., Singh, S. R., & Dennis, V. A. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02431 · Cited by 113
“The SOCS box interacts with Elongins (B and C) to recruit E2 ubiquitin–transferase, necessary for negative regulation of cytokine signaling (Kamizono et al., 2001).”
BackgroundSasaki, A. T., Inagaki‐Ohara, K., Yoshida, T., Yamanaka, A., Sasaki, M., Yasukawa, H., Koromilas, A. E., & Yoshimura, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200608200 · Cited by 114
Self-citationNegative Regulation of Cytokine and TLR Signalings by SOCS and Others
Naka, T., Fujimoto, M., Tsutsui, H., & Yoshimura, A. (2005) · Advances in immunology · doi:10.1016/s0065-2776(05)87003-8 · Cited by 107
Self-citationThe Emerging Role of the COP9 Signalosome in Cancer
Richardson, K. S., & Zundel, W. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0233 · Cited by 101
“Indeed, just the recognition components in the F-box, BTB, and SOCS/BC families number f600 in humans, suggesting that a significant portion of the proteome could be regulated by the CSN. Importantly, several of these Cullin-based E3s (Cul-E3) have major significance in multiple aspects of cancer initiation and progre…”
The role of cullin 5-containing ubiquitin ligases
Okumura, F., Akiko, J.-O., Nakatsukasa, K., & Kamura, T. (2016) · Cell Division · doi:10.1186/s13008-016-0016-3 · Cited by 105
Regulation of cytokine signaling by the SOCS and Spred family proteins.
Yoshimura, A. (2009) · The Keio Journal of Medicine · doi:10.2302/kjm.58.73 · Cited by 108
Self-citationNicholson, S. E., Metcalf, D., Sprigg, N. S., Columbus, R., Walker, F., Silva, A., Cary, D., Willson, T. A., Zhang, J., Hilton, D. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409675102 · Cited by 112
The SOCS2 Ubiquitin Ligase Complex Regulates Growth Hormone Receptor Levels
Vesterlund, M., Zadjali, F., Persson, T., Nielsen, M. L., Kessler, B. M., Norstedt, G., & Flores‐Morales, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025358 · Cited by 97
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
Medves, S., & Demoulin, J. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01415.x · Cited by 104
“The forced expression of SOCS1-induced apoptosis of Ba/F3 cells expressing ETV6-JAK2 via the ubiquitindependant hybrid proteolysis [107].”
Olière, S., Hernandez, E., Lézin, A., Arguello, M., Douville, R. N., Nguyên, T. L.-A., Olindo, S., Panelatti, G., Kazanji, M., Wilkinson, P. A., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001177 · Cited by 102
“Indeed, the SOCS box-mediated function of SOCS1 is chiefly exerted via its ubiquitin ligase activity [62] and biochemical binding studies have shown that the SOCS box interacts with the elongin B/C complex, a component of the ubiquitin/proteasome pathway that forms an E3 ligase with Cul2 (or Cul5) and Rbx-1 [40,58].”
BackgroundJAK Kinases in Health and Disease: An Update
Laurence, A. D. J., Pesu, M., Silvennoinen, O., & O’Shea, J. J. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010232 · Cited by 104
“Intriguingly, the mutation-based constitutive activation of JAK can still be controlled by induced expression of specific JAK signaling inhibitors such as SOCS1 or by kinase inhibitors that are currently used in clinical trials [74, 75].”
BackgroundHuang, F.-J., Steeg, P., Price, J., Chiu, W.-T., Chou, P.-C., Xie, K., Sawaya, R., & Huang, S.-Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1429 · Cited by 92
“Because the degradation of JAK2 is affected by SOCS-1 protein level (17, 18), we then examined the endogenous expression of SOCS-1 in cultures of A375P and A375Br cells.”
Bhattacharyya, S., Zhao, Y., Kay, T. W. H., & Muglia, L. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017296108 · Cited by 93
“One potential mechanism for SOCS1-mediated STAT1 suppression is the degradation of phosphorylated JAK2, the key upstream component for STAT1 phosphorylation and activation (12, 25, 26).”
BackgroundAli, S., Nouhi, Z., Chughtai, N., & Ali, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306758200 · Cited by 111
Ott, N., Faletti, L. E., Heeg, M., Andreani, V., & Grimbacher, B. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01483-x · Cited by 96
“On the other hand, SOCS proteins mark STATs for proteasomal degradation by the SOCS box motif [13, 14], which can recruit factors including Elongin B/C, Cul5, RBX1, and RBX2 initiating the ubiquitylation cascade [15-17].”
BackgroundSekine, Y., Yumioka, T., Yamamoto, T., Muromoto, R., Imoto, S., Sugiyma, K., Oritani, K., Shimoda, K., Minoguchi, M., Akira, S., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.380 · Cited by 91
“The SOCS-box recruits the Elongin B, C-Rbx1-Cul2 ubiquitination system (41), suggesting that ubiquitination may be involved in SOCS1-mediated suppression of TRAF6-dependent IKK activation (42).”
BackgroundSelf-citation
Metadata
- Authors
- Kamizono, S., Hanada, T., Yasukawa, H., Minoguchi, S., Kato, R., Minoguchi, M., Hattori, K., Hatakeyama, S., Yada, M., Morita, S., Kitamura, T., Kato, H., Nakayama, K.-I., & Yoshimura, A.
- Affiliations
- Kurume University (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Corresponding author
- Yoshimura, Akihiko
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-04
- Volume
- 276
- Issue
- 16
- Pages
- 12530-12538
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2124489640
- Cited by
- 311
- References
- 38
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 4 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 10 · 2019: 9 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 6 · 2014: 11 · 2013: 8 · 2012: 22
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7127 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- SOCS1, SOCS box, ubiquitin-mediated proteolysis, E3 ubiquitin ligase, CUL2, JAK2 tyrosine kinase, leukemia, ubiquitination, SH2 domain, apoptosis
- MeSH terms
- Suppressor of Cytokine Signaling 1 Protein, Elongin, ETS Translocation Variant 6 Protein, Animals, Binding Sites, Carrier Proteins, Cell Division, Cell Line, Chromosomes, Human, Pair 12, Chromosomes, Human, Pair 9, Humans, Kinetics, Leukemia, Phosphorylation, Recombinant Fusion Proteins, Recombinant Proteins, Repressor Proteins, Transcription Factors, Transfection, Ubiquitins, Oncogene Proteins, Fusion, Mutagenesis, Cell Cycle Proteins, src Homology Domains, Cullin Proteins, Intracellular Signaling Peptides and Proteins, Suppressor of Cytokine Signaling Proteins, Mice, Janus Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.